Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance
Get Alerts JAZZ Hot Sheet
Price: $107.67 -0.6%
Revenue Growth %: +7.1%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +7.1%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.52, $0.04 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $348.15 million.
Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.60, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015 revenue of $1.32-1.34 million, versus the consensus of $1.36 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbus revenue rises, delivers 142 commercial aircraft in Q1
- Southern Copper Corp. (SCCO) Tops Q1 EPS by 20c
- Deutsche Bank (DB) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!